Next Article in Journal / Special Issue
Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy
Previous Article in Journal
To Die or to Survive, a Fatal Question for the Destiny of Prostate Cancer Cells after Androgen Deprivation Therapy
Previous Article in Special Issue
Tissue Transglutaminase (TG2)-Induced Inflammation in Initiation, Progression, and Pathogenesis of Pancreatic Cancer

Epidermal Growth Factor Receptor in Pancreatic Cancer

Hepatobiliary Surgery Unit, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, UK
Genetic Medicine, MAHSC, University of Manchester, St Mary’s Hospital, Oxford Road, Manchester, M13 9WL, UK
Author to whom correspondence should be addressed.
Cancers 2011, 3(2), 1513-1526;
Received: 5 February 2011 / Revised: 28 February 2011 / Accepted: 11 March 2011 / Published: 24 March 2011
(This article belongs to the Special Issue Pancreatic Cancer)
Pancreatic cancer is the fourth leading cause of cancer related death. The difficulty in detecting pancreatic cancer at an early stage, aggressiveness and the lack of effective therapy all contribute to the high mortality. Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein, which is expressed in normal human tissues. It is a member of the tyrosine kinase family of growth factors receptors and is encoded by proto-oncogenes. Several studies have demonstrated that EGFR is over-expressed in pancreatic cancer. Over-expression correlates with more advanced disease, poor survival and the presence of metastases. Therefore, inhibition of the EGFR signaling pathway is an attractive therapeutic target. Although several combinations of EGFR inhibitors with chemotherapy demonstrate inhibition of tumor-induced angiogenesis, tumor cell apoptosis and regression in xenograft models, these benefits remain to be confirmed. Multimodality treatment incorporating EGFR-inhibition is emerging as a novel strategy in the treatment of pancreatic cancer. View Full-Text
Keywords: EGFR; mutation; expression; pancreatic cancer EGFR; mutation; expression; pancreatic cancer
Show Figures

MDPI and ACS Style

Oliveira-Cunha, M.; Newman, W.G.; Siriwardena, A.K. Epidermal Growth Factor Receptor in Pancreatic Cancer. Cancers 2011, 3, 1513-1526.

AMA Style

Oliveira-Cunha M, Newman WG, Siriwardena AK. Epidermal Growth Factor Receptor in Pancreatic Cancer. Cancers. 2011; 3(2):1513-1526.

Chicago/Turabian Style

Oliveira-Cunha, Melissa, William G. Newman, and Ajith K. Siriwardena 2011. "Epidermal Growth Factor Receptor in Pancreatic Cancer" Cancers 3, no. 2: 1513-1526.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop